Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics
- Acronyms N-Dur
- 19 Feb 2018 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 06 Jul 2016 Status changed from not yet recruiting to recruiting.